Pharmaceutical production

AUMED is preparing the production of a mass-produced medical product. Under the contract manufacturing regime, AUMED wants to become a manufacturer of the STAFAL medicine, which, on the basis of bacteriophage, as an active substance, addresses one of the possible alternative ways to combat the growing resistance to antibiotics. STAFAL is a unique authorized product in the EU. The safety and effectiveness of the medicine is validated by many years of use in the medical field.

With this step, the company significantly expands its portfolio of professional activities in the field of human immunobiological issues, which is one of its thematic priorities.